CRS vs. KNSA
CRS (Carpenter Technology Corporation) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. CRS operates in Metal Fabrication (Industrials), while KNSA operates in Biotechnology (Healthcare). Over the past 5 years, CRS returned 70.73%/yr vs 37.13%/yr for KNSA. Their 0.21 correlation means their historical movements had little consistent relationship.
Performance
CRS vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRS achieves a 65.23% return, which is significantly lower than KNSA's 80.22% return.
CRS
- 1D
- 3.17%
- 1M
- -14.83%
- 6M
- 63.58%
- YTD
- 65.23%
- 1Y
- 108.94%
- 3Y*
- 106.41%
- 5Y*
- 70.73%
- 10Y*
- 32.06%
- ALL TIME*
- 14.12%
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $455.19M | $399.26M | $397.99M | |
| $68.75M | $54.52M | $46.86M |
CRS vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CRS Carpenter Technology Corporation | 65.23% | 86.23% | 141.72% | 94.48% | 29.50% | 2.66% | -39.44% | 42.12% | -39.60% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between CRS and KNSA is 0.12, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.12 |
Correlation (3Y) Balances recent behavior with more history. | 0.22 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.21 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.21 |
The correlation between CRS and KNSA shifts across timeframes, from 0.12 (1 year) to 0.22 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
CRS:
$25.82B
KNSA:
$5.67B
CRS:
$10.53
KNSA:
$1.00
CRS:
49.34
KNSA:
74.38
CRS:
0.04
KNSA:
0.72
CRS:
8.37
KNSA:
7.14
CRS:
11.71
KNSA:
9.48
CRS:
$3.12B
KNSA:
$840.85M
CRS:
$955.40M
KNSA:
$546.22M
CRS:
$797.60M
KNSA:
$111.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRS vs. KNSA — Risk / Return Rank
CRS
KNSA
CRS vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Carpenter Technology Corporation (CRS) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRS | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.69 | ||
| Sortino ratioReturn per unit of downside risk | -1.03 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.52 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 5.87 | 6.94 | -1.07 |
| Martin ratioReturn relative to average drawdown | 20.89 | 24.13 | -3.24 |
Loading charts...
Drawdowns
CRS vs. KNSA - Drawdown Comparison
The maximum CRS drawdown since its inception was -84.68%, roughly equal to the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for CRS and KNSA.
Loading charts...
Drawdown Indicators
| CRS | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.68% | -83.06% | -1.62% |
Max Drawdown (1Y)Largest decline over 1 year | -18.66% | -21.12% | +2.46% |
Max Drawdown (3Y)Largest decline over 3 years | -28.74% | -34.14% | +5.40% |
Max Drawdown (5Y)Largest decline over 5 years | -41.86% | -53.17% | +11.31% |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | — | — |
Current DrawdownCurrent decline from peak | -16.08% | -8.13% | -7.95% |
Average DrawdownAverage peak-to-trough decline | -27.16% | -40.09% | +12.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.23% | 6.06% | -0.83% |
Volatility
CRS vs. KNSA - Volatility Comparison
The current volatility for Carpenter Technology Corporation (CRS) is 14.21%, while Kiniksa Pharmaceuticals, Ltd. (KNSA) has a volatility of 26.47%. This indicates that CRS experiences smaller price fluctuations and is considered to be less risky than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRS | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.21% | 26.47% | -12.26% |
Volatility (6M)Calculated over the trailing 6-month period | 33.58% | 41.55% | -7.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 50.12% | 49.77% | +0.35% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 46.58% | 54.77% | -8.19% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 48.87% | 64.34% | -15.47% |
Dividends
CRS vs. KNSA - Dividend Comparison
CRS's dividend yield for the trailing twelve months is around 0.15%, while KNSA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRS Carpenter Technology Corporation | 0.15% | 0.25% | 0.47% | 1.13% | 2.17% | 2.74% | 2.75% | 1.61% | 2.13% | 1.41% | 1.99% | 2.38% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
CRS vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Carpenter Technology Corporation and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CRS vs. KNSA - Profitability Comparison
CRS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Carpenter Technology Corporation reported a gross profit of 268.90M and revenue of 851.00M. Therefore, the gross margin over that period was 31.6%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
CRS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Carpenter Technology Corporation reported an operating income of 206.90M and revenue of 851.00M, resulting in an operating margin of 24.3%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
CRS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Carpenter Technology Corporation reported a net income of 162.40M and revenue of 851.00M, resulting in a net margin of 19.1%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
Frequently Asked Questions
CRS and KNSA have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (26.47%) compared to CRS (14.21%). In terms of maximum drawdown, CRS dropped -84.68% vs KNSA's -83.06%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 2.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRS and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer